- Home
- ARQT vs NRIX Comparison
ARQT vs NRIX Comparison
Compare ARQT & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARQT | NRIX |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ARQT | NRIX |
|---|---|---|
| Price | $28.84 | $24.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $38.38 | $34.36 |
| AVG Volume (30 Days) | ★ 2.9M | 1.6M |
| Earning Date | 10-27-2026 | 10-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.79 | N/A |
| EPS | 0.03 | ★ 3.26 |
| Revenue | ★ $376,072,000.00 | $76,987,000.00 |
| Revenue This Year | $43.01 | $786.93 |
| Revenue Next Year | $27.70 | N/A |
| P/E Ratio | $970.00 | ★ $7.64 |
| Revenue Growth | 91.34 | ★ 99.31 |
| 52 Week Low | $19.30 | $9.93 |
| 52 Week High | $31.77 | $28.23 |
Technical Indicators
Market Signals| Indicator | ARQT | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 62.77 | 56.10 |
| Support Level | $24.91 | $22.48 |
| Resistance Level | $30.30 | $24.65 |
| Average True Range (ATR) | 1.20 | 1.10 |
| MACD | 0.32 | 0.24 |
| Stochastic Oscillator | 84.07 | 81.70 |
Price Performance
Historical ComparisonAbout ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.